Soleus Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Soleus Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-51,686	Closed	-$4.04M	–	110
2023 Q1	$4.04M	Buy	51,686 +39,186	+313%	+$4.54M	0.42%	54
2022 Q4	$1.04M	Sell	12,500 -39,186	-76%	-$3.15M	0.15%	64
2022 Q3	$4.75M	Hold	51,686	–	–	0.65%	44
2022 Q2	$7.73M	Hold	51,686	–	–	1.21%	30
2022 Q1	$12.5M	Buy	51,686 +43,093	+501%	+$11.3M	1.62%	24
2021 Q4	$2.6M	Sell	8,593 -657	-7%	-$210K	0.26%	51
2021 Q3	$3.83M	Buy	+9,250	New	+$3.22M	0.6%	41
2021 Q2	–	Sell	-6,250	Closed	-$1.28M	–	78
2021 Q1	$1.28M	Hold	6,250	–	–	0.23%	61
2020 Q4	$1.25M	Hold	6,250	–	–	0.16%	49
2020 Q3	$1.03M	Buy	+6,250	New	+$1.42M	0.55%	42

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Soleus Capital Management's PVLA Position: Q2 2023 in Review

Soleus Capital Management sold out of Palvella Therapeutics (PVLA) in Q2 2023, closing a stake of 51,686 shares — an estimated $4.04M sold.

Soleus Capital Management first reported a position in PVLA in Q3 2020 and held it in 10 quarters. The position peaked at $12.5M in Q1 2022. 49 funds tracked by Wall St. Rank hold PVLA as of Q2 2023.

Soleus Capital Management reported no remaining Palvella Therapeutics position as of Q2 2023 after selling out during the quarter.
Soleus Capital Management sold 51,686 Palvella Therapeutics shares in Q2 2023, an estimated $4.04M.
Soleus Capital Management first reported a position in Palvella Therapeutics in Q3 2020 and held it in 10 quarters.
Soleus Capital Management's Palvella Therapeutics position peaked at $12.5M in Q1 2022.
49 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2023.

Based on Soleus Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.